Capex / expansionFiled on BSE ·
Lord's Mark Industries completes Phase I expansion at Silvassa facility ahead of schedule
Lords Mark Industries · Commercial Services & Supplies
What the filing says
- Phase I expansion completed nearly three months early, before December 2026
- Surgical and orthopaedic product portfolio expanded from 36 to 54 SKUs with 18 new products
- New production line to begin commercial operations on October 11, 2026; new SKUs pending US FDA approval expected by December 2026
Original filing
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Completion Of Phase I Expansion At Silvassa Facility Ahead Of Schedule.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Lords Mark Industries
Other capex / expansion filings this fortnight
- Capex / expansionStudds Accessor.Studds Accessories updates delay and new expected start for Manufacturing Facility-V
- Capex / expansionBondada Engineering LtdBondada Engineering commissions 221.7 MWp solar projects in Q2 FY27
- Capex / expansionJayaswal Neco Industries LtdJayaswal Neco Industries achieves financial closure for 1.5 MnTPA pellet plant expansion
- Capex / expansionACME Solar Holdings LtdACME Solar commissions additional 107.36 MW / 437.49 MWh BESS capacity in Rajasthan
- Capex / expansionLloyds MetalsLloyds Metals & Energy reports record H1FY27 production across key segments
- Capex / expansionAdani Green Energy LtdAdani Green Energy operationalizes 481.9 MW renewable and 6.63 GWh BESS projects
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.